PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF OBE022, A SELECTIVE PROSTAGLANDIN F2A RECEPTOR ANTAGONIST TOCOLYTIC: A FIRST-IN-HUMAN TRIAL IN HEALTHY POSTMENOPAUSAL WOMEN.

Pohl O.; Marchant L.; Gotteland J. -P.; Coates S.; Taubel J.; Lorch U.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF OBE022, A SELECTIVE PROSTAGLANDIN F2A RECEPTOR ANTAGONIST TOCOLYTIC: A FIRST-IN-HUMAN TRIAL IN HEALTHY POSTMENOPAUSAL WOMEN.

【24h】

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF OBE022, A SELECTIVE PROSTAGLANDIN F2A RECEPTOR ANTAGONIST TOCOLYTIC: A FIRST-IN-HUMAN TRIAL IN HEALTHY POSTMENOPAUSAL WOMEN.

机译：OBE022的药代动力学，安全性和可耐受性，一种选择性前列腺素F2A受体拮抗剂拮抗剂：在健康绝经后妇女中的一部分试验。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2019年第1期|共2页
作者
Pohl O.; Marchant L.; Gotteland J. -P.; Coates S.; Taubel J.; Lorch U.;
展开▼
作者单位

ObsEva SA Geneva Switzerland;

ObsEva SA Geneva Switzerland;

ObsEva SA Geneva Switzerland;

Richmond Pharmacol Ltd London England;

Richmond Pharmacol Ltd London England;

Richmond Pharmacol Ltd London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
入库时间 2022-08-19 23:48:23

相似文献

外文文献
中文文献
专利

1. PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF OBE022, A SELECTIVE PROSTAGLANDIN F2A RECEPTOR ANTAGONIST TOCOLYTIC: A FIRST-IN-HUMAN TRIAL IN HEALTHY POSTMENOPAUSAL WOMEN. [J] . Pohl O., Marchant L., Gotteland J. -P., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：OBE022的药代动力学，安全性和可耐受性，一种选择性前列腺素F2A受体拮抗剂拮抗剂：在健康绝经后妇女中的一部分试验。
2. PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF ACT-539313, A NOVEL SELECTIVE OREXIN-1 RECEPTOR ANTAGONIST, IN A FIRST-IN-HUMAN STUDY. [J] . Kaufmann P., Kornberger R., Dingemanse J. Clinical Pharmacology and Therapeutics . 2018,第Suppla1期

机译：在一生的研究中，ACT-539313的药代动力学，药效学，安全性和可耐受性，一种新的选择性orexin-1受体拮抗剂。
3. PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF ACT-539313, A NOVEL SELECTIVE OREXIN-1 RECEPTOR ANTAGONIST, IN A FIRST-IN-HUMAN STUDY. [J] . Kaufmann P., Kornberger R., Dingemanse J. Clinical Pharmacology and Therapeutics . 2018,第Suppla1期

机译：在一生的研究中，ACT-539313的药代动力学，药效学，安全性和可耐受性，一种新的选择性orexin-1受体拮抗剂。
4. Safety, tolerability, pharmacodynamics and pharmacokinetics following single subcutaneous dosesof a teverelix depot formulation in healthy male volunteers [C] . C. MacLean, F. Larsen, R. Piechatzek, Annual meeting exposition of the Controlled Release Society . 2005

机译：在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性，耐受性，药效动力学和药代动力学
5. Pharmacokinetics safety and tolerability of OBE022 a selective prostaglandin F2α receptor antagonist tocolytic: A first‐in‐human trial in healthy postmenopausal women [O] . Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, 2018

机译：OBE022（一种选择性前列腺素F2α受体拮抗剂）的药代动力学安全性和耐受性：在健康的绝经后妇女中进行的首次人体试验
6. Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese Subjects [O] . Luning Sun, Li Ding, Yongqing Wang, 2013

机译：新型选择性毒蕈碱型M1 / M3受体拮抗药溴环十二烷溴化物的药代动力学，安全性和耐受性，在健康受试者中进行了一次和多次鼻内给药后

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF OBE022, A SELECTIVE PROSTAGLANDIN F2A RECEPTOR ANTAGONIST TOCOLYTIC: A FIRST-IN-HUMAN TRIAL IN HEALTHY POSTMENOPAUSAL WOMEN.

著录项

相似文献

相关主题

期刊订阅